A fundamental flaw driving very low success in drug R&D is that existing disease models do not reliably represent human biology. We have developed transformational disease models, which apply principles of physiological blood flow to tissue from patients to recapitulate human disease. These models, in combination with powerful computational science, are the core of our REVEAL-Tx™ platform that enables unprecedented insights into complex human diseases.

To date, our platform has been used to recreate nearly 20 human disease states related to liver, vascular and tumor biology, including those driving our current pipeline in several rare disorders and nonalcoholic steatohepatitis (NASH), a global liver disease. REVEAL-Tx™ reduces the risk of failure by enabling us to deeply interrogate human disease, identify meaningful therapeutic targets and assess drug candidates under physiological disease conditions.

We leverage our REVEAL-Tx™ platform for our proprietary drug discovery programs and for partnerships with companies who are interested in novel approaches to disease treatments.